1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Schibli, D.J. Hunter, H.N. Aseyev, V. Starner, T.D. Wiencek, J.M. McCray Jr., P.B. Tack, B.F. Vogel, H.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 277 8279 8289 10.1074/jbc.M108830200 11741980 The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. 2002 10.2210/pdb1kj5/pdb pdb_00001kj5 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 3940.598 BETA-DEFENSIN 1 1 man polymer HBD-1, DEFENSIN, BETA 1 no no DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia sample 9606 Homo sapiens 562 Escherichia coli database_2 pdbx_nmr_software pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2002-03-20 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name _pdbx_nmr_spectrometer.model Solution Structure of Human beta-Defensin 3 RCSB Y RCSB 2001-12-04 REL This structure was determined using standard 2D homonuclear techniques. structures with the lowest energy 100 20 2D NOESY 2D TOCSY 2D COSY 2D NOESY 2D TOCSY 3.79 ambient 298 K distance geometry, simulated annealing, molecular dynamics 1 closest to the average 0.5 mM HBD1 90% H2O/10% D2O 0.5 mM HBD1 100% D2O Bruker collection XwinNMR 2.6 Delaglio, G., Grzejiek, S., Vuister, G., Zhu, G., Pfeifer, J., Bax, A. processing NMRPipe 1.8 Johnson, B.A., Blevins, R.A. data analysis NMRView 4.1.3 A.T.Brunger, P.D.Adams, G.M.Clore, W.L.Delano, P.Gros, R.W.Grosse-Kunstleve, J.-S.Jiang, J.Kuszewski, M.Nilges, N.S.Pannu, R.J.Read, L.M.Rice, T.Simonson, G.L.Warren refinement CNS 1.0 J.Linge, S.O'Donoghue, M.Nilges refinement ARIA 1.0 500 Bruker AVANCE 800 Varian INOVA ASP 1 n 1 ASP 1 A HIS 2 n 2 HIS 2 A TYR 3 n 3 TYR 3 A ASN 4 n 4 ASN 4 A CYS 5 n 5 CYS 5 A VAL 6 n 6 VAL 6 A SER 7 n 7 SER 7 A SER 8 n 8 SER 8 A GLY 9 n 9 GLY 9 A GLY 10 n 10 GLY 10 A GLN 11 n 11 GLN 11 A CYS 12 n 12 CYS 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A SER 15 n 15 SER 15 A ALA 16 n 16 ALA 16 A CYS 17 n 17 CYS 17 A PRO 18 n 18 PRO 18 A ILE 19 n 19 ILE 19 A PHE 20 n 20 PHE 20 A THR 21 n 21 THR 21 A LYS 22 n 22 LYS 22 A ILE 23 n 23 ILE 23 A GLN 24 n 24 GLN 24 A GLY 25 n 25 GLY 25 A THR 26 n 26 THR 26 A CYS 27 n 27 CYS 27 A TYR 28 n 28 TYR 28 A ARG 29 n 29 ARG 29 A GLY 30 n 30 GLY 30 A LYS 31 n 31 LYS 31 A ALA 32 n 32 ALA 32 A LYS 33 n 33 LYS 33 A CYS 34 n 34 CYS 34 A CYS 35 n 35 CYS 35 A LYS 36 n 36 LYS 36 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N LEU 13 A N LEU 13 A O LYS 33 A O LYS 33 A O CYS 34 A O CYS 34 A N GLY 25 A N GLY 25 1 A ASN 4 -66.57 86.08 1 A CYS 5 -106.86 -74.32 1 A PRO 18 -77.06 -78.94 1 A ILE 19 -56.63 -172.10 1 A PHE 20 -77.94 41.41 1 A CYS 27 -83.87 -95.39 1 A TYR 28 -61.51 -156.61 2 A CYS 5 -98.30 -70.00 2 A PRO 18 -91.01 -75.39 2 A ILE 19 -56.02 -176.47 2 A PHE 20 -74.88 32.15 2 A THR 21 -78.86 -152.82 2 A LYS 22 -165.17 94.07 2 A CYS 27 -89.64 -85.48 2 A TYR 28 -61.37 -158.23 3 A ASN 4 -66.11 84.36 3 A CYS 5 -102.26 -69.21 3 A PRO 18 -81.49 -70.04 3 A ILE 19 -56.59 -173.24 3 A PHE 20 -74.51 25.91 3 A THR 21 -76.74 -163.04 3 A LYS 22 -163.60 108.23 3 A CYS 27 -83.44 -91.30 3 A TYR 28 -61.49 -156.18 4 A ASN 4 -68.91 85.63 4 A CYS 5 -109.53 -79.05 4 A PRO 18 -90.80 -79.98 4 A ILE 19 -56.60 -168.30 4 A PHE 20 -75.69 33.97 4 A CYS 27 -95.27 -78.06 4 A TYR 28 -60.94 -164.65 5 A PRO 18 -76.43 -83.30 5 A ILE 19 -56.53 -171.18 5 A PHE 20 -69.96 15.48 5 A THR 21 -63.15 -172.71 5 A CYS 27 -94.37 -78.47 5 A TYR 28 -60.12 -176.92 6 A CYS 5 -102.54 -72.43 6 A PRO 18 -89.75 -73.34 6 A ILE 19 -56.47 -173.45 6 A PHE 20 -78.10 40.03 6 A CYS 27 -93.18 -92.71 6 A TYR 28 -61.24 -160.49 7 A PRO 18 -79.05 -80.70 7 A ILE 19 -56.56 -170.34 7 A PHE 20 -76.00 35.56 7 A GLN 24 -107.75 -66.98 7 A CYS 27 -100.56 -84.52 7 A TYR 28 -61.12 -160.52 8 A HIS 2 -60.24 96.08 8 A TYR 3 -57.51 172.66 8 A PRO 18 -88.43 -72.50 8 A ILE 19 -55.92 -176.01 8 A PHE 20 -76.62 32.17 8 A THR 21 -83.37 -154.30 8 A CYS 27 -81.89 -88.39 8 A TYR 28 -62.12 -153.41 9 A CYS 5 -97.76 -65.21 9 A PRO 18 -90.63 -72.96 9 A ILE 19 -56.13 -170.97 9 A PHE 20 -71.03 23.12 9 A LYS 22 -161.97 117.31 9 A CYS 27 -82.99 -91.29 9 A TYR 28 -60.94 -168.02 10 A CYS 5 -101.30 -63.54 10 A PRO 18 -87.78 -72.46 10 A ILE 19 -56.37 -169.85 10 A PHE 20 -76.64 36.01 10 A CYS 27 -84.35 -96.15 10 A TYR 28 -61.65 -144.06 11 A CYS 5 -100.80 -72.96 11 A PRO 18 -89.38 -73.65 11 A ILE 19 -56.47 -174.21 11 A CYS 27 -71.85 -85.09 11 A TYR 28 -60.84 -168.46 12 A ASN 4 -64.09 91.58 12 A CYS 5 -119.51 -75.87 12 A PRO 18 -90.94 -80.37 12 A ILE 19 -56.17 -172.38 12 A PHE 20 -75.84 36.60 12 A CYS 27 -85.97 -80.50 12 A TYR 28 -60.27 -173.72 13 A HIS 2 -59.98 109.25 13 A CYS 5 -103.89 -76.29 13 A PRO 18 -89.84 -81.59 13 A ILE 19 -56.57 -173.95 13 A PHE 20 -71.62 21.36 13 A CYS 27 -81.90 -79.30 13 A TYR 28 -61.28 -160.50 14 A HIS 2 -59.61 109.92 14 A CYS 5 -99.66 -67.43 14 A PRO 18 -88.28 -71.87 14 A ILE 19 -56.97 -168.76 14 A PHE 20 -73.43 23.43 14 A THR 21 -65.23 -169.45 14 A CYS 27 -80.89 -88.40 14 A TYR 28 -61.23 -161.69 15 A ASN 4 -64.50 86.41 15 A CYS 5 -116.82 -74.54 15 A VAL 6 -55.65 -8.17 15 A CYS 17 -39.60 112.52 15 A PRO 18 -83.56 -72.60 15 A ILE 19 -56.46 -172.80 15 A PHE 20 -72.92 24.56 15 A THR 21 -76.88 -162.99 15 A CYS 27 -91.40 -87.59 15 A TYR 28 -61.08 -164.01 16 A CYS 5 -118.06 -78.54 16 A PRO 18 -84.01 -75.42 16 A ILE 19 -56.36 -172.48 16 A PHE 20 -75.34 33.50 16 A CYS 27 -93.75 -83.59 16 A TYR 28 -60.85 -169.45 17 A VAL 6 -55.68 -8.08 17 A PRO 18 -86.98 -77.14 17 A ILE 19 -56.54 -171.74 17 A CYS 27 -88.08 -82.47 17 A TYR 28 -61.13 -165.95 18 A HIS 2 -59.89 104.35 18 A CYS 5 -109.21 -65.01 18 A PRO 18 -79.30 -83.92 18 A ILE 19 -56.17 -176.07 18 A PHE 20 -76.30 35.19 18 A THR 21 -75.90 -152.46 18 A LYS 22 -160.45 108.59 18 A CYS 27 -100.67 -78.74 18 A TYR 28 -60.30 -174.69 19 A CYS 5 -114.93 -74.58 19 A PRO 18 -90.05 -72.67 19 A ILE 19 -56.02 -172.92 19 A PHE 20 -74.47 33.13 19 A THR 21 -81.17 -150.78 19 A LYS 22 -167.11 108.71 19 A GLN 24 -108.94 -69.93 19 A CYS 27 -94.15 -92.80 19 A TYR 28 -61.40 -156.29 20 A HIS 2 -60.91 94.91 20 A CYS 5 -130.34 -82.42 20 A PRO 18 -89.18 -78.62 20 A ILE 19 -56.45 -171.93 20 A PHE 20 -69.77 19.80 20 A THR 21 -73.25 -159.63 20 A LYS 22 -160.63 117.82 20 A CYS 27 -86.44 -81.88 20 A TYR 28 -61.02 -165.27 Solution Structure of Human beta-defensin 1 1 N N disulf 2.030 A CYS 5 A SG CYS 5 1_555 A CYS 34 A SG CYS 34 1_555 disulf 2.030 A CYS 12 A SG CYS 12 1_555 A CYS 27 A SG CYS 27 1_555 disulf 2.027 A CYS 17 A SG CYS 17 1_555 A CYS 35 A SG CYS 35 1_555 ANTIBIOTIC Defensin, antimicrobial protein, human beta-defensin 1, beta-defensin, HBD1, ANTIBIOTIC BD01_HUMAN UNP 1 33 P60022 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK 33 68 1KJ5 1 36 P60022 A 1 1 36 3 anti-parallel anti-parallel A GLN 11 A GLN 11 A LEU 13 A LEU 13 A LYS 33 A LYS 33 A CYS 35 A CYS 35 A ILE 23 A ILE 23 A THR 26 A THR 26